257 related articles for article (PubMed ID: 28777866)
1. [Association of Val66Met polymorphism of brain-derived neurotrophic factor gene with cognitive impairment and clinical symptoms in first episode schizophrenia].
Zhang C; Gu X; Wang Q; Li M; Deng W; Guo W; Zhao L; Ma X; Li T
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Aug; 34(4):592-596. PubMed ID: 28777866
[TBL] [Abstract][Full Text] [Related]
2. [Association study of brain-derived neurotrophic factor Val66Met polymorphism and clinical characteristics of first episode schizophrenia].
Sun MM; Liu LF; Yang LM; Wang Y; Cui KY; Wang LN; Li CL; Qiao DD; Wang RZ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):155-8. PubMed ID: 22487823
[TBL] [Abstract][Full Text] [Related]
3. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers.
Ho BC; Milev P; O'Leary DS; Librant A; Andreasen NC; Wassink TH
Arch Gen Psychiatry; 2006 Jul; 63(7):731-40. PubMed ID: 16818862
[TBL] [Abstract][Full Text] [Related]
4. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms.
Numata S; Ueno S; Iga J; Yamauchi K; Hongwei S; Ohta K; Kinouchi S; Shibuya-Tayoshi S; Tayoshi S; Aono M; Kameoka N; Sumitani S; Tomotake M; Kaneda Y; Taniguchi T; Ishimoto Y; Ohmori T
Neurosci Lett; 2006 Jun; 401(1-2):1-5. PubMed ID: 16533563
[TBL] [Abstract][Full Text] [Related]
5. Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders.
Mezquida G; Penadés R; Cabrera B; Savulich G; Lobo A; González-Pinto A; Penzol MJ; Corripio I; Fernandez-Egea E; Gassó P; Cuesta MJ; Bernardo M;
Eur Psychiatry; 2016 Oct; 38():61-69. PubMed ID: 27668551
[TBL] [Abstract][Full Text] [Related]
6. Smoking and BDNF Val66Met polymorphism in male schizophrenia: a case-control study.
Zhang XY; Chen DC; Tan YL; Luo X; Zuo L; Lv MH; Shah NN; Zunta-Soares GB; Soares JC
J Psychiatr Res; 2015 Jan; 60():49-55. PubMed ID: 25455509
[TBL] [Abstract][Full Text] [Related]
7. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene.
Rybakowski JK; Borkowska A; Skibinska M; Szczepankiewicz A; Kapelski P; Leszczynska-Rodziewicz A; Czerski PM; Hauser J
Psychiatry Clin Neurosci; 2006 Feb; 60(1):70-6. PubMed ID: 16472361
[TBL] [Abstract][Full Text] [Related]
8. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia.
Koolschijn PC; van Haren NE; Bakker SC; Hoogendoorn ML; Hulshoff Pol HE; Kahn RS
Hippocampus; 2010 Sep; 20(9):1010-7. PubMed ID: 19714565
[TBL] [Abstract][Full Text] [Related]
9. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder.
Matsuo K; Walss-Bass C; Nery FG; Nicoletti MA; Hatch JP; Frey BN; Monkul ES; Zunta-Soares GB; Bowden CL; Escamilla MA; Soares JC
Neuropsychopharmacology; 2009 Jul; 34(8):1904-13. PubMed ID: 19295510
[TBL] [Abstract][Full Text] [Related]
10. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Mak M; Deptuła-Jarosz M; Gołąb-Janowska M; Droździk M; Sławek J
Neurosci Lett; 2014 Feb; 561():86-90. PubMed ID: 24394906
[TBL] [Abstract][Full Text] [Related]
11. The impact of BDNF Val66Met polymorphism on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.
Mandolini GM; Lazzaretti M; Pigoni A; Delvecchio G; Soares JC; Brambilla P
J Affect Disord; 2019 Jan; 243():552-558. PubMed ID: 30078664
[TBL] [Abstract][Full Text] [Related]
12. Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease.
Pivac N; Nikolac M; Nedic G; Mustapic M; Borovecki F; Hajnsek S; Presecki P; Pavlovic M; Mimica N; Muck Seler D
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):356-62. PubMed ID: 21044653
[TBL] [Abstract][Full Text] [Related]
13. The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia.
Chen SL; Lee SY; Chang YH; Chen SH; Chu CH; Wang TY; Chen PS; Lee IH; Yang YK; Hong JS; Lu RB
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():99-104. PubMed ID: 24468644
[TBL] [Abstract][Full Text] [Related]
14. BDNF Val66Met polymorphism is associated with Stage III-IV endometriosis and poor in vitro fertilization outcome.
Zhang QY; Guan Q; Wang Y; Feng X; Sun W; Kong FY; Wen J; Cui W; Yu Y; Chen ZY
Hum Reprod; 2012 Jun; 27(6):1668-75. PubMed ID: 22447624
[TBL] [Abstract][Full Text] [Related]
15. BDNF val66met modulates the association between childhood trauma, cognitive and brain abnormalities in psychoses.
Aas M; Haukvik UK; Djurovic S; Bergmann Ø; Athanasiu L; Tesli MS; Hellvin T; Steen NE; Agartz I; Lorentzen S; Sundet K; Andreassen OA; Melle I
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():181-8. PubMed ID: 23876786
[TBL] [Abstract][Full Text] [Related]
16. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia.
Lu W; Zhang C; Yi Z; Li Z; Wu Z; Fang Y
J Mol Neurosci; 2012 Jul; 47(3):505-10. PubMed ID: 22477643
[TBL] [Abstract][Full Text] [Related]
17. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.
Ng T; Teo SM; Yeo HL; Shwe M; Gan YX; Cheung YT; Foo KM; Cham MT; Lee JA; Tan YP; Fan G; Yong WS; Preetha M; Loh WJ; Koo SL; Jain A; Lee GE; Wong M; Dent R; Yap YS; Ng R; Khor CC; Ho HK; Chan A
Neuro Oncol; 2016 Feb; 18(2):244-51. PubMed ID: 26289590
[TBL] [Abstract][Full Text] [Related]
18. Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease.
Gomar JJ; Conejero-Goldberg C; Huey ED; Davies P; Goldberg TE;
Neurobiol Aging; 2016 Mar; 39():165-73. PubMed ID: 26923413
[TBL] [Abstract][Full Text] [Related]
19. Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease.
Nagata T; Shinagawa S; Nukariya K; Yamada H; Nakayama K
Dement Geriatr Cogn Disord; 2012; 33(4):266-72. PubMed ID: 22699449
[TBL] [Abstract][Full Text] [Related]
20. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis.
Smith GN; Thornton AE; Lang DJ; Macewan GW; Ehmann TS; Kopala LC; Tee K; Shiau G; Voineskos AN; Kennedy JL; Honer WG
Schizophr Res; 2012 Feb; 134(2-3):253-9. PubMed ID: 22192502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
